Accufy Diagnostics discloses $2 million equity offering in SEC Form D filing

Accufy Diagnostics, Inc. filed a Form D with the Securities and Exchange Commission disclosing an exempt securities offering, with a signature date of October 28, 2026. The filing is listed as a new notice, with a date of first sale of October 15, 2026.¹

The company, incorporated in Delaware, was formed within the last five years, in 2023.¹ Its principal place of business is listed at 13 Taft Court, Suite 219, in Rockville, Maryland.¹ The filing classifies the issuer's industry group as biotechnology within health care.¹

The filing names Jeffrey Hung and Zhixiong Xu as related persons, each listed as an executive officer and director.¹ Hung signed the form as Chief Executive Officer.

On the offering terms, Accufy claimed the Rule 506(b) exemption under Regulation D.¹ The securities offered were equity.¹ The filing states the offering was not made in connection with a business combination transaction such as a merger, acquisition or exchange offer.¹

The minimum investment accepted from any outside investor was $300,000.¹ The total offering amount and total amount sold were both listed as $2,000,000, with $0 remaining to be sold.¹ The filing reports three investors have already invested in the offering.¹

No sales commissions or finder's fees were reported, and both were listed as $0.¹ The amount of proceeds proposed for use to pay executive officers, directors or promoters was also listed as $0.¹ The issuer's revenue or net asset value range was listed as "decline to disclose."¹